127 related articles for article (PubMed ID: 26925253)
1. Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.
Alten R; Nüßlein H; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Pavelka K; Chartier M; Poncet C; Rauch C; Elbez Y; Le Bars M
RMD Open; 2016; 2(1):e000228. PubMed ID: 26925253
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Peichl P; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
Clin Exp Rheumatol; 2016; 34(3):489-99. PubMed ID: 26966919
[TBL] [Abstract][Full Text] [Related]
3. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.
Alten R; Mariette X; Lorenz HM; Galeazzi M; Cantagrel A; Nüßlein HG; Chartier M; Elbez Y; Rauch C; Le Bars M
RMD Open; 2017; 3(2):e000538. PubMed ID: 29435360
[TBL] [Abstract][Full Text] [Related]
4. Safety profile of abatacept in rheumatoid arthritis: a review.
Khraishi M; Russell A; Olszynski WP
Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
[TBL] [Abstract][Full Text] [Related]
5. The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy.
Kissin EY
Clin Ther; 2014 Jul; 36(7):1114-6. PubMed ID: 24996488
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study.
Tanaka Y; Kubo S; Yamanaka H; Amano K; Hirata S; Tanaka E; Nagasawa H; Yasuoka H; Takeuchi T
Mod Rheumatol; 2014 Sep; 24(5):754-62. PubMed ID: 25036232
[TBL] [Abstract][Full Text] [Related]
7. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
Weinblatt M; Combe B; Covucci A; Aranda R; Becker JC; Keystone E
Arthritis Rheum; 2006 Sep; 54(9):2807-16. PubMed ID: 16947384
[TBL] [Abstract][Full Text] [Related]
8. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
Sato E; Tanaka E; Ochiai M; Shimizu Y; Kobayashi A; Shidara K; Hoshi D; Sugimoto N; Inoue E; Seto Y; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
[TBL] [Abstract][Full Text] [Related]
9. Role of abatacept in the management of rheumatoid arthritis.
Nogid A; Pham DQ
Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
11. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
[TBL] [Abstract][Full Text] [Related]
12. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
Kremer JM; Dougados M; Emery P; Durez P; Sibilia J; Shergy W; Steinfeld S; Tindall E; Becker JC; Li T; Nuamah IF; Aranda R; Moreland LW
Arthritis Rheum; 2005 Aug; 52(8):2263-71. PubMed ID: 16052582
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.
Westhovens R; Robles M; Ximenes AC; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Murthy B
Ann Rheum Dis; 2015 Mar; 74(3):564-8. PubMed ID: 25550337
[TBL] [Abstract][Full Text] [Related]
14. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.
Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Takemoto T; Terabe K; Asai N; Ishiguro N
J Rheumatol; 2015 May; 42(5):786-93. PubMed ID: 25834204
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B.
Kim PS; Ho GY; Prete PE; Furst DE
Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1265-8. PubMed ID: 22392695
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
[TBL] [Abstract][Full Text] [Related]
17. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
[TBL] [Abstract][Full Text] [Related]
18. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
19. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.
Sibilia J; Westhovens R
Clin Exp Rheumatol; 2007; 25(5 Suppl 46):S46-56. PubMed ID: 17977488
[TBL] [Abstract][Full Text] [Related]
20. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
